Exploiting the kinetic interplay between GPIbα-VWF binding interfaces to regulate hemostasis and thrombosis.

Area of Science:

• Biophysics
• Hematology
• Molecular Biology

Background:

• Platelet-von Willebrand factor (VWF) interactions are crucial for hemostasis and thrombosis.
• The role of specific bond properties between platelet glycoprotein Ibα and VWF A1 domain remains unclear.

Purpose of the Study:

• To investigate how the kinetic interplay of VWF-platelet binding surfaces influences VWF-platelet interactions.
• To elucidate the impact of altered bond kinetics on hemostasis and thrombosis.

Main Methods:

• Utilized VWF-A1 knock-in mice with mutations (I1309V, R1326H) altering glycoprotein Ibα binding.
• Assessed hemostatic and thrombotic defects in mutant mice.
• Examined human platelet aggregation in response to an allosteric inhibitor.

Main Results:

• The R1326H mutation shortened VWF-platelet bond lifetime, causing hemostatic and thrombotic defects similar to VWF deficiency.
• An allosteric inhibitor disrupting VWF-A1 binding impaired platelet aggregation in arterioles.
• The I1309V mutation prolonged bond lifetime, leading to a type 2B-like von Willebrand disease phenotype.
• Combining R1326H and I1309V mutations normalized bond kinetics and restored normal hemostatic/thrombotic function.

Conclusions:

• The kinetic properties of the VWF-platelet bond significantly influence platelet binding and thrombus formation.
• Targeting VWF-platelet bond kinetics offers potential therapeutic strategies for bleeding and thrombotic disorders.
• Combined biophysical and genetic approaches are vital for understanding VWF-mediated diseases.